Kirstine Nørregaard
Advancement of a novel ADC for hard-to-treat cancers
From left to right: Niels Behrendt, Alba Martinez Perlado, Kirstine Sandal Nørregaard and Lars Henning Engelholm
Applicant
Kirstine Nørregaard
Project description
With this project, we aim to improve the outcome for currently hard-to-treat cancers with the development of a novel antibody-drug conjugate (ADC). ADCs are a groundbreaking and promising class of targeted anti-cancer drugs. The molecular target of our ADC is a unique and promising target, as it is overexpressed on a wide variety of solid cancers. Notably, this includes several cancer types that currently lack effective treatment options, and our current focus indications include triple-negative breast cancer, squamous cell lung carcinoma, sarcoma and glioblastoma. In pre-clinical mouse cancer models, treatment with our ADC resulted in prominent tumor regression and significantly extended survival. During the SPARK programme, we will further develop our ADC and generally mature the project in order to move it towards commercialization, with the ultimate goal of providing a novel targeted treatment option to benefit patients suffering from hard-to-treat cancers.
Institution
University of Copenhagen
SPARK information
Kirstine and her team were accepted as part of cohort 5.